JPWO2021121367A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021121367A5 JPWO2021121367A5 JP2022537297A JP2022537297A JPWO2021121367A5 JP WO2021121367 A5 JPWO2021121367 A5 JP WO2021121367A5 JP 2022537297 A JP2022537297 A JP 2022537297A JP 2022537297 A JP2022537297 A JP 2022537297A JP WO2021121367 A5 JPWO2021121367 A5 JP WO2021121367A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- lung cancer
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 102000008300 Mutant Proteins Human genes 0.000 claims 3
- 108010021466 Mutant Proteins Proteins 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 102200006538 rs121913530 Human genes 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Claims (12)
前記癌が、膵臓癌、大腸癌又は肺癌から選択される、医薬組成物。 A pharmaceutical composition for use according to claim 4 , comprising:
A pharmaceutical composition, wherein the cancer is selected from pancreatic cancer , colon cancer, or lung cancer.
前記肺癌が、非小細胞肺癌である、医薬組成物。 A pharmaceutical composition, wherein the lung cancer is non-small cell lung cancer.
前記癌が、膵臓癌、大腸癌又は肺癌から選択される、使用。 The use according to claim 7 ,
The use, wherein said cancer is selected from pancreatic cancer , colon cancer or lung cancer.
前記肺癌が、非小細胞肺癌である、使用。 The use, wherein the lung cancer is non-small cell lung cancer.
前記癌が、膵臓癌、大腸癌又は肺癌から選択される、使用。 The use, wherein said cancer is selected from pancreatic cancer, colon cancer or lung cancer.
前記肺癌が、非小細胞肺癌である、使用。 The use, wherein the lung cancer is non-small cell lung cancer.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019126687 | 2019-12-19 | ||
| CNPCT/CN2019/126687 | 2019-12-19 | ||
| CN2020070885 | 2020-01-08 | ||
| CNPCT/CN2020/070885 | 2020-01-08 | ||
| CN2020073723 | 2020-01-22 | ||
| CNPCT/CN2020/073723 | 2020-01-22 | ||
| CNPCT/CN2020/078565 | 2020-03-10 | ||
| CN2020078565 | 2020-03-10 | ||
| PCT/CN2020/137497 WO2021121367A1 (en) | 2019-12-19 | 2020-12-18 | Kras mutant protein inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506532A JP2023506532A (en) | 2023-02-16 |
| JPWO2021121367A5 true JPWO2021121367A5 (en) | 2023-12-25 |
Family
ID=76478185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537297A Pending JP2023506532A (en) | 2019-12-19 | 2020-12-18 | KRAS mutant protein inhibitor |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11180506B2 (en) |
| EP (1) | EP4077326A4 (en) |
| JP (1) | JP2023506532A (en) |
| KR (1) | KR20220119088A (en) |
| CN (4) | CN115192577B (en) |
| AU (1) | AU2020404319A1 (en) |
| BR (1) | BR112022011421A2 (en) |
| CA (1) | CA3165238A1 (en) |
| CL (1) | CL2022001670A1 (en) |
| CO (1) | CO2022010098A2 (en) |
| CR (1) | CR20220351A (en) |
| IL (1) | IL293962A (en) |
| MX (1) | MX2022007527A (en) |
| PE (1) | PE20230161A1 (en) |
| TW (1) | TW202128691A (en) |
| WO (1) | WO2021121367A1 (en) |
| ZA (2) | ZA202207450B (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3919483A4 (en) * | 2019-01-29 | 2022-02-09 | Brightgene Bio-medical Technology Co., Ltd. | Benzopyridone heterocyclic compound and use thereof |
| US11453683B1 (en) | 2019-08-29 | 2022-09-27 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
| MX2022003537A (en) | 2019-09-24 | 2022-07-11 | Mirati Therapeutics Inc | Combination therapies. |
| JP7340100B2 (en) | 2019-10-28 | 2023-09-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Small Molecule Inhibitor of KRAS G12C Mutant |
| CN115192577B (en) * | 2019-12-19 | 2024-03-29 | 北京加科思新药研发有限公司 | KRAS mutein inhibitors |
| KR20220119094A (en) | 2019-12-19 | 2022-08-26 | 아비나스 오퍼레이션스, 인코포레이티드 | Compounds and methods for targeted degradation of androgen receptors |
| KR20220130126A (en) | 2019-12-20 | 2022-09-26 | 미라티 테라퓨틱스, 인크. | SOS1 inhibitor |
| CN114671866A (en) * | 2020-12-25 | 2022-06-28 | 苏州泽璟生物制药股份有限公司 | Aryl or heteroaryl pyridone or pyrimidone derivative and preparation method and application thereof |
| WO2021249563A1 (en) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | Aryl or heteroaryl pyridone or pyrimidone derivative, preparation method therefor and application thereof |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| PE20231207A1 (en) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | INDOLIC DERIVATIVES AS RAS INHIBITORS IN CANCER TREATMENT |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | Ras inhibitors for the treatment of cancer |
| KR20240004960A (en) | 2021-05-05 | 2024-01-11 | 레볼루션 메디슨즈, 인크. | RAS inhibitors |
| CN117295742A (en) * | 2021-05-12 | 2023-12-26 | 北京加科思新药研发有限公司 | New forms of compound I and their use |
| KR20240041917A (en) | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | Medicines for the treatment and/or prevention of cancer |
| CN115894520A (en) * | 2021-09-23 | 2023-04-04 | 上海和誉生物医药科技有限公司 | Macrocyclic K-RAS G12C inhibitor, preparation method and pharmaceutical application thereof |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| TW202340214A (en) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519402A1 (en) * | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| JOP20190272A1 (en) * | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| WO2019099524A1 (en) * | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3741756B1 (en) * | 2018-01-19 | 2023-11-01 | Medshine Discovery Inc. | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
| WO2019241157A1 (en) * | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| MX2020012261A (en) * | 2018-06-12 | 2021-03-31 | Amgen Inc | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer. |
| CN115192577B (en) * | 2019-12-19 | 2024-03-29 | 北京加科思新药研发有限公司 | KRAS mutein inhibitors |
-
2020
- 2020-12-18 CN CN202210597916.4A patent/CN115192577B/en active Active
- 2020-12-18 TW TW109145045A patent/TW202128691A/en unknown
- 2020-12-18 AU AU2020404319A patent/AU2020404319A1/en active Pending
- 2020-12-18 CR CR20220351A patent/CR20220351A/en unknown
- 2020-12-18 PE PE2022001137A patent/PE20230161A1/en unknown
- 2020-12-18 IL IL293962A patent/IL293962A/en unknown
- 2020-12-18 JP JP2022537297A patent/JP2023506532A/en active Pending
- 2020-12-18 CN CN202080014581.8A patent/CN113454083A/en active Pending
- 2020-12-18 BR BR112022011421A patent/BR112022011421A2/en unknown
- 2020-12-18 MX MX2022007527A patent/MX2022007527A/en unknown
- 2020-12-18 CA CA3165238A patent/CA3165238A1/en active Pending
- 2020-12-18 EP EP20903388.5A patent/EP4077326A4/en active Pending
- 2020-12-18 CN CN202111058976.0A patent/CN113651814B/en active Active
- 2020-12-18 WO PCT/CN2020/137497 patent/WO2021121367A1/en unknown
- 2020-12-18 KR KR1020227024638A patent/KR20220119088A/en unknown
- 2020-12-18 CN CN202111617953.9A patent/CN114349750A/en active Pending
-
2021
- 2021-03-10 US US17/197,095 patent/US11180506B2/en active Active
- 2021-08-20 US US17/407,418 patent/US11787811B2/en active Active
- 2021-12-27 US US17/562,492 patent/US20220213109A1/en active Pending
-
2022
- 2022-06-17 CL CL2022001670A patent/CL2022001670A1/en unknown
- 2022-07-05 ZA ZA2022/07450A patent/ZA202207450B/en unknown
- 2022-07-18 CO CONC2022/0010098A patent/CO2022010098A2/en unknown
- 2022-08-05 ZA ZA2022/08783A patent/ZA202208783B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021121367A5 (en) | ||
| JP2022121594A5 (en) | ||
| JP2022009090A5 (en) | ||
| JP2022191257A5 (en) | ||
| JP2018109022A5 (en) | ||
| JP2015523397A5 (en) | ||
| JP2009538327A5 (en) | ||
| DAVE et al. | Azathioprine in the treatment of muco‐cutaneous pemphigoid | |
| RU2007145489A (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND ITS METASTASES | |
| EA200800881A1 (en) | DOSAGE FORM OF PYRFENIDONE IN THE FORM OF CAPSULES WITH PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS | |
| JP2017526700A5 (en) | ||
| JP2008536853A5 (en) | ||
| JP2018533560A5 (en) | ||
| JP2020521797A5 (en) | ||
| JP2014525454A5 (en) | ||
| JP2023537600A (en) | Replicative stress pathway agent compositions and methods for treating cancer | |
| JP2019533660A5 (en) | ||
| JP2019524888A5 (en) | ||
| JP2018516936A5 (en) | ||
| JP2019536790A5 (en) | ||
| JP2021504384A5 (en) | ||
| RU2020108192A (en) | THERAPEUTIC COMBINATION OF THIRD GENERATION TYROSINE KINASE INHIBITOR EGFR AND RAF INHIBITOR | |
| BR112019026029A2 (en) | ORAL PHARMACEUTICAL FORMULATIONS OF REMOGLIFLOZINE | |
| JP2019516728A (en) | Anti-cancer combination treatment | |
| RU2017124612A (en) | COMBINATION OF 6-OXO-1, 6-DIHYDRO-PYRIDAZONE DERIVATIVE, ANTI-CANCER ACTIVITY, AND REFR INHIBITOR |